These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8276240)

  • 1. p53 domains: identification and characterization of two autonomous DNA-binding regions.
    Wang Y; Reed M; Wang P; Stenger JE; Mayr G; Anderson ME; Schwedes JF; Tegtmeyer P
    Genes Dev; 1993 Dec; 7(12B):2575-86. PubMed ID: 8276240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of p53 with its consensus DNA-binding site.
    Wang Y; Schwedes JF; Parks D; Mann K; Tegtmeyer P
    Mol Cell Biol; 1995 Apr; 15(4):2157-65. PubMed ID: 7891710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 domains: structure, oligomerization, and transformation.
    Wang P; Reed M; Wang Y; Mayr G; Stenger JE; Anderson ME; Schwedes JF; Tegtmeyer P
    Mol Cell Biol; 1994 Aug; 14(8):5182-91. PubMed ID: 8035799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation.
    Reed M; Woelker B; Wang P; Wang Y; Anderson ME; Tegtmeyer P
    Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9455-9. PubMed ID: 7568153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 oligomerization and DNA looping are linked with transcriptional activation.
    Stenger JE; Tegtmeyer P; Mayr GA; Reed M; Wang Y; Wang P; Hough PV; Mastrangelo IA
    EMBO J; 1994 Dec; 13(24):6011-20. PubMed ID: 7813439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity.
    Bayle JH; Elenbaas B; Levine AJ
    Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5729-33. PubMed ID: 7777576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein.
    Bargonetti J; Manfredi JJ; Chen X; Marshak DR; Prives C
    Genes Dev; 1993 Dec; 7(12B):2565-74. PubMed ID: 8276239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization.
    Shieh SY; Taya Y; Prives C
    EMBO J; 1999 Apr; 18(7):1815-23. PubMed ID: 10202145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots.
    Pavletich NP; Chambers KA; Pabo CO
    Genes Dev; 1993 Dec; 7(12B):2556-64. PubMed ID: 8276238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain.
    Roth J; Koch P; Contente A; Dobbelstein M
    Oncogene; 2000 Mar; 19(14):1834-42. PubMed ID: 10777217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.
    Lin J; Chen J; Elenbaas B; Levine AJ
    Genes Dev; 1994 May; 8(10):1235-46. PubMed ID: 7926727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serine phosphorylation in the NH2 terminus of p53 facilitates transactivation.
    Mayr GA; Reed M; Wang P; Wang Y; Schweds JF; Tegtmeyer P
    Cancer Res; 1995 Jun; 55(11):2410-7. PubMed ID: 7757994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
    Liu WL; Midgley C; Stephen C; Saville M; Lane DP
    J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of p53 DNA binding activity by point mutation.
    Marston NJ; Ludwig RL; Vousden KH
    Oncogene; 1998 Jun; 16(24):3123-31. PubMed ID: 9671391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function.
    Lubin DJ; Butler JS; Loh SN
    J Mol Biol; 2010 Jan; 395(4):705-16. PubMed ID: 19913028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDMX: a novel p53-binding protein with some functional properties of MDM2.
    Shvarts A; Steegenga WT; Riteco N; van Laar T; Dekker P; Bazuine M; van Ham RC; van der Houven van Oordt W; Hateboer G; van der Eb AJ; Jochemsen AG
    EMBO J; 1996 Oct; 15(19):5349-57. PubMed ID: 8895579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xenopus laevis p53 protein: sequence-specific DNA binding, transcriptional regulation and oligomerization are evolutionarily conserved.
    Wang Y; Farmer G; Soussi T; Prives C
    Oncogene; 1995 Feb; 10(4):779-84. PubMed ID: 7862457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of baculovirus recombinant wild-type p53. Dimerization of p53 is required for high-affinity DNA binding and cysteine oxidation inhibits p53 DNA binding.
    Delphin C; Cahen P; Lawrence JJ; Baudier J
    Eur J Biochem; 1994 Jul; 223(2):683-92. PubMed ID: 8055938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of DNA sequences that are specifically bound by wild-type p53 protein.
    Foord O; Navot N; Rotter V
    Mol Cell Biol; 1993 Mar; 13(3):1378-84. PubMed ID: 8441383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of transactivation and transrepression function, and not RPA binding, alters growth suppression by p53.
    Leiter LM; Chen J; Marathe T; Tanaka M; Dutta A
    Oncogene; 1996 Jun; 12(12):2661-8. PubMed ID: 8700525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.